New hope for tough cancers: first test of targeted drug for KRAS mutation

NCT ID NCT06179160

Recruiting now Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

Summary

This is the first study in people to test a new drug called INCB161734, which is designed to target a specific genetic change (KRAS G12D mutation) found in some advanced solid tumors. The main goals are to find a safe dose and see how well the drug is tolerated, both by itself and when combined with other cancer therapies. The study will enroll about 710 adults whose cancer has progressed despite standard treatments or who have no other good options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre Leon Berard
RECRUITING

Lyon, 69373, France
Centro Ricerche Cliniche Di Verona
RECRUITING

Verona, 37134, Italy
Chris Obrien Lifehouse
RECRUITING

Camperdown, New South Wales, 02050, Australia
Cliniques Universitaires Ucl Saint-Luc
RECRUITING

Brussels, 01200, Belgium
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Fondazione Irccs Istituto Nazionale Dei Tumori
RECRUITING

Milan, 20133, Italy
Fundacion Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
Hospital General Universitario Vall D Hebron
RECRUITING

Barcelona, 08035, Spain
Hospital Universitario Quironsalud Madrid
RECRUITING

Madrid, 28223, Spain
Institut Gustave Roussy
RECRUITING

Villejuif, 94805, France
Irccs Istituto Clinico Humanitas
RECRUITING

Rozzano, 20089, Italy
Jefferson University Hospitals
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Linear Clinical Research
RECRUITING

Nedlands, Western Australia, 06009, Australia
Mayo Clinic Hospital
RECRUITING

Phoenix, Arizona, 85054, United States
Md Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10022, United States
National Cancer Center Hospital East
RECRUITING

Chiba, 277-0882, Japan
Peter Maccallum Cancer Centre
RECRUITING

North Melbourne, Victoria, 3051, Australia
Princess Margaret Cancer Center
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Sarah Cannon Research Institue At Healthone
RECRUITING

Denver, Colorado, 80218, United States
Scri Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
RECRUITING

Baltimore, Maryland, 21287, United States
St Vincent'S Hospital Sydney
RECRUITING

Darlinghurst, New South Wales, 02010, Australia
Stanford University
RECRUITING

Palo Alto, California, 94305, United States
The Alfred Hospital
RECRUITING

Melbourne, Victoria, 03004, Australia
The Cancer Institute Hospital of Jfcr
RECRUITING

Tokyo, 135-0063, Japan
The Ottawa Hospital Cancer Center
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada
UCLA Healthcare Hematology-Oncology
RECRUITING

Santa Monica, California, 90404, United States
Universitair Ziekenhuis (Uz) Leuven
RECRUITING

Leuven, 03000, Belgium
Universitair Ziekenhuis Antwerpen (Uza)
RECRUITING

Edegem, 02650, Belgium
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole
RECRUITING

Toulouse, 31059, France
Weill Cornell Medicine
RECRUITING

New York, New York, 10021, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMORS